Misdiagnosis Common in Parkinsonian Disorders - Summary - MDSpire

Misdiagnosis Common in Parkinsonian Disorders

Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.

  • By

  • Andrea Surnit

  • June 8, 2026

  • 4 min

Share

Objective:

To investigate the rates of clinical misdiagnosis in Parkinsonian disorders and the factors influencing diagnostic accuracy.

Key Findings:
  • Misdiagnosis rates ranged from approximately 10% to 20% across Parkinsonian disorders.
  • Clinical diagnoses of Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies corresponded with underlying Lewy body pathology in 92% of cases.
  • Donors with dementia-associated parkinsonism were nearly twice as likely to have Lewy body pathology compared to those with Parkinson's disease without dementia.
  • Autopsy findings in patients diagnosed with corticobasal syndrome frequently revealed other pathologies such as progressive supranuclear palsy.
  • 40% of patients with Lewy body disease had coexisting Alzheimer's disease pathology.
Interpretation:

Clinical features alone do not fully capture the biological heterogeneity of Parkinsonian disorders, indicating the need for improved diagnostic approaches.

Limitations:
  • Potential referral and sampling bias due to reliance on brain bank cohorts.
  • Variability in pathologic assessment across centers and time periods.
  • Incomplete documentation of co-pathologies.
  • Limited representation of non-European ancestry groups.
Conclusion:

The study emphasizes the importance of integrating genetic and pathologic data to enhance diagnostic accuracy in Parkinsonian disorders.

Original Source(s)

Misdiagnosis Common in Parkinsonian Disorders

  • by Andrea Surnit

  • June 8, 2026

Related Content

Self-Sampling Shows Test Agreement

The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.